Niagen Bioscience Inc. (NASDAQ:NAGE) is one of the high-growth micro-cap stocks to buy now. On June 2, Niagen Bioscience Inc. (NASDAQ:NAGE) renamed the ChromaDex External Research Program (CERP) to the Niagen Research Program to underscore its renewed focus on advancing the understanding and applications of NAD+.
Pressmaster/Shutterstock.com
Over the years, the company has focused on building a scientific foundation for NAD+ research through rigorous collaboration with leading independent investigators. Independent investigators from world-renowned institutions such as Mayo Clinic, the National Institutes of Health, and Cambridge University have repeatedly requested Niagen for its preclinical research and NAD+ biology.
Research under the program continues to explore NAD+ and Niagen across various areas of skeletal and brain tissues, cellular energy metabolism, and cardiovascular health. The program also supports more than 175 ongoing and developing research studies. It also provides oral Niagen research materials, including food-grade and pharmaceutical-grade products, as well as technical support.
Niagen Bioscience Inc. (NASDAQ:NAGE) is a global bioscience company focused on healthy aging and cellular health research. They are the innovators and patent holders of Niagen (nicotinamide riboside, or NR), a breakthrough ingredient clinically proven to boost NAD+ levels and support DNA repair and mitochondrial function.
While we acknowledge the potential of NAGE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: Billionaire Ken Fisher’s Top 12 High-Growth Stock Picks and 12 Best Tech Stocks to Invest In on the Dip.
Disclosure: None. Follow Insider Monkey on Google News.